基线不确定性慢性乙型肝炎不同分型及分期转换的肝细胞癌风险差异
这项回顾性队列研究纳入来自九个国家和地区的1986例不确定性慢性乙型肝炎患者(94.2%为亚洲人),按基线HBeAg、ALT和HBV DNA分型。20年肝细胞癌累积发生率在1型最高(36.2%),8型最低(1.9%);转为免疫耐受期或免疫活动期的患者累积发生率较高。结论认为部分不确定性慢性乙型肝炎类型肝细胞癌风险高,数据支持潜在扩大治疗标准。
要点
- 不确定性慢性乙型肝炎患者中HBeAg阴性者占84.9%。
- 20年肝细胞癌累积发生率1型36.2%最高,8型1.9%最低。
- 转为免疫耐受期15年累积发生率16.5%,转为免疫活动期20年13.7%。
核心结论
- 多种不确定性慢性乙型肝炎类型具有高肝细胞癌风险,数据支持潜在扩大高风险类型的治疗标准。
研究设计与样本
- 回顾性队列研究,纳入来自九个国家和地区的1986例不确定性慢性乙型肝炎患者,其中94.2%为亚洲人。
- 按基线HBeAg、ALT和HBV DNA对患者进行分型,比较肝细胞癌累积发生率。
主要发现
- 基于2018年美国肝病研究学会指南,大多数不确定性患者为HBeAg阴性(84.9%)。
- 20年肝细胞癌发生率在1型最高(HBeAg阳性、ALT<1×正常上限、HBV DNA 20000-10^6 IU/mL,36.2%),在8型最低(HBeAg阴性、ALT 1-2×正常上限、HBV DNA<2000 IU/mL,1.9%)。
- 持续不确定性者的20年肝细胞癌发生率为4.7%。
- 转为免疫耐受期者15年累积肝细胞癌发生率为16.5%,转为免疫活动期者20年为13.7%,转为免疫非活动期者20年为2.5%。
- 多因素分析中,以8型为参照,HBeAg阳性1型调整HR=40.1(p<0.001),2型(ALT 1-2×正常上限、HBV DNA≥20000 IU/mL)调整HR=25.1(p<0.001),HBeAg阴性9型(ALT>2×正常上限、HBV DNA<2000 IU/mL)调整HR=4.6(p=0.032),10型(ALT<1×正常上限、HBV DNA<2000 IU/mL但伴中重度炎症/纤维化)调整HR=7.3(p=0.033)。
关键数值与推荐
- 不确定性慢性乙型肝炎1型:HBeAg阳性、ALT<1×正常上限、HBV DNA 20000-10^6 IU/mL,20年肝细胞癌发生率36.2%。
- 不确定性慢性乙型肝炎8型:HBeAg阴性、ALT 1-2×正常上限、HBV DNA<2000 IU/mL,20年肝细胞癌发生率1.9%。
- 不确定性慢性乙型肝炎2型:ALT 1-2×正常上限、HBV DNA≥20000 IU/mL,以8型为参照调整HR=25.1(p<0.001)。
- 不确定性慢性乙型肝炎9型:HBeAg阴性、ALT>2×正常上限、HBV DNA<2000 IU/mL,以8型为参照调整HR=4.6(p=0.032)。
- 不确定性慢性乙型肝炎10型:ALT<1×正常上限、HBV DNA<2000 IU/mL但伴中重度炎症/纤维化,以8型为参照调整HR=7.3(p=0.033)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with chronic hepatitis B (CHB) with indeterminate phase make up a diverse cohort with likely different outcomes. OBJECTIVE: We compared the hepatocellular carcinoma (HCC) risk in indeterminate CHB with different baseline types and by phase transition. DESIGN: This was a retrospective cohort study of 1986 (94.2% Asian) patients with indeterminate CHB from nine countries/regions. Patients were classified according to baseline hepatitis B e-antigen (HBeAg), alanine aminotransferase (ALT) and HBV DNA. The cumulative HCC incidence was compared. RESULTS: Based on the 2018 American Association for the Study of Liver Disease guidance, most indeterminate patients were HBeAg negative (84.9%). The 20-year HCC incidence was highest in type 1 (HBeAg positive, ALT<1×upper limit of normal (ULN), HBV DNA 20 000-106 IU/mL, 36.2%) and lowest in type 8 (HBeAg negative, ALT 1-2×ULN, HBV DNA<2000 IU/mL, 1.9%). The 20-year HCC incidence of those who remained indeterminate was 4.7%. Cumulative HCC incidence rates were high in patients with indeterminate CHB who transitioned to immune tolerant (15 years: 16.5%) or immune active (20 years: 13.7%) phase but low for those who transitioned to immune inactive phase (20 years: 2.5%). In multivariable analysis, compared with type 8, higher HCC risk was seen with HBeAg-positive type 1 (adjusted HR (aHR)=40.1, p<0.001), type 2 (ALT 1-2×ULN, HBV DNA≥20 000 IU/mL, aHR=25.1, p<0.001), HBeAg-negative type 9 (ALT>2×ULN, HBV DNA<2000 IU/mL, aHR=4.6, p=0.032) and type 10 (ALT<1×ULN, HBV DNA<2000 IU/mL but with moderate to severe inflammation/fibrosis, aHR=7.3, p=0.033). Similar directions in HCC risks were found in analyses based on the 2017 European Association for the Study of the Liver guideline. CONCLUSION: Several types of indeterminate CHB had high HCC risk. These data support the potential expansion of treatment criteria for higher risk types of indeterminate CHB.
引用
- Huang R, Trinh HN, Yasuda S, et al. Differential HCC risk among HBV indeterminate types at baseline and by phase transition. Gut. 2025. PMID: 40467102. doi:10.1136/gutjnl-2025-335033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。